Show simple item record

dc.contributor.authorLynch, Karen
dc.contributor.authorFarrell, Michael
dc.date.accessioned2011-03-31T12:55:23Z
dc.date.available2011-03-31T12:55:23Z
dc.date.issued2010-10
dc.identifier.citationCerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment. 2010, 29 (10):1201-4 Clin. Rheumatol.en
dc.identifier.issn1434-9949
dc.identifier.pmid20419463
dc.identifier.doi10.1007/s10067-010-1466-7
dc.identifier.urihttp://hdl.handle.net/10147/126567
dc.description.abstractWe report a case of a cerebral tuberculoma in a 60-year-old woman with rheumatoid arthritis while receiving the anti-tumor necrosis factor alpha monoclonal antibody, adalimumab (Humira), for active disease. MR brain imaging for dyspraxia revealed a left parietal ring-enhancing lesion, which on resection was shown to be a necrotizing granuloma. There were no associated pulmonary lesions, and the patient was systemically well. Sputum and urine cultures were negative for tuberculosis. The patient was treated with anti-tuberculous medications and made an excellent recovery. We consider this to be the first documented case of tuberculosis involving the central nervous system occurring in the setting of adalimumab treatment.
dc.language.isoenen
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntirheumatic Agents
dc.subject.meshArthritis, Rheumatoid
dc.subject.meshBrain Diseases
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshParietal Lobe
dc.subject.meshTreatment Outcome
dc.subject.meshTuberculoma, Intracranial
dc.titleCerebral tuberculoma in a patient receiving anti-TNF alpha (adalimumab) treatment.en
dc.typeArticleen
dc.contributor.departmentDepartment of Neuropathology, Beaumont Hospital, Beaumont, Dublin 9, Ireland. karenlynch81@gmail.comen
dc.identifier.journalClinical rheumatologyen
dc.description.provinceLeinster
html.description.abstractWe report a case of a cerebral tuberculoma in a 60-year-old woman with rheumatoid arthritis while receiving the anti-tumor necrosis factor alpha monoclonal antibody, adalimumab (Humira), for active disease. MR brain imaging for dyspraxia revealed a left parietal ring-enhancing lesion, which on resection was shown to be a necrotizing granuloma. There were no associated pulmonary lesions, and the patient was systemically well. Sputum and urine cultures were negative for tuberculosis. The patient was treated with anti-tuberculous medications and made an excellent recovery. We consider this to be the first documented case of tuberculosis involving the central nervous system occurring in the setting of adalimumab treatment.


This item appears in the following Collection(s)

Show simple item record